{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-23-000052","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2023-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.720140+00:00","generated_at":"2026-06-10T14:34:49.632298+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AnaptysBio Chairman James Topper resigns; John Orwin named Chairman","bullets":["James Topper resigned as Class II director and Chairman effective Sept 15, 2023; no disagreement with company.","Topper will serve as advisor to the Board through Q1 2024 under an Advisory Agreement.","John Orwin appointed Class II director and Chairman on Sept 15, 2023.","Orwin received initial equity grants: option for 3,311 shares (vesting monthly to Jan 2024) and 2,035 RSUs (vest at 2024 annual meeting).","Orwin also granted option for 10,600 shares (3-year monthly vest) and 3,900 RSUs (3-year annual vest)."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-23-000052","json":"https://secwatch.observer/filing/0001370053-23-000052.json","markdown":"https://secwatch.observer/filing/0001370053-23-000052.md","text":"https://secwatch.observer/filing/0001370053-23-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000052/0001370053-23-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000052/anab-20230914.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T14:34:49.632298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ab52f4e8d","claim":"John Orwin was appointed as Chairman at ANAPTYSBIO, INC.","evidence_excerpt":"On September 15, 2023, the Board appointed John Orwin as a Class II director, a member of the Nominating and Corporate Governance Committee and Chairman of the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000052/0001370053-23-000052-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman"}],"fact_type":"executive_change"},{"claim_id":"ebc76b8c9e","claim":"James N. Topper resigned as Chairman at ANAPTYSBIO, INC.","evidence_excerpt":"On September 14, 2023, James N. Topper, M.D., Ph.D., advised the Board of Directors (the “ Board ”) of AnaptysBio, Inc. (the “ Company ”) that he would resign as a Class II director and as Chairman of the Board, effective on September 15, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000052/0001370053-23-000052-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}